Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity

Table 5 Comparison with acute toxicity data reported in the literature

Ref.	No. pts	SIB	d/fx	CHT	Gastrointestinal		Genitourinary		Skin		Hematologic
					G2	G3	G2	G3	G2	G3	G2	G3	G4
Pepek et al[26], 2010	29	No	1.8	89%	76%	10%	45%	3%	100%	0	45%	24%
Bazan et al[24], 2010	29	Yes	1.6-1.8	86%	\	7%	\	\	\	21%	\	21%
Vieillot et al[28], 2012	72	No	1.8-2.0	85%	14%	4%	4%	2%	16%	16%	4%	5%	4%
DeFoe et al[11], 2012	78	No	1.8	98%	60%	27.7%	18.5%	0	91.3%	29%	51.4%	42.9%	12.9%
Kachnic et al[5], 2012	43	Yes	1.5-1.8	100%	42%	7%	5%	5%	63%	5%	21%	49%	12%
Kachnic et al[13], 2012	52	Yes	1.5-1.8	100%	52%	21%	13.4%	1.9%	52%	21%	15.4%	30%	27%
Chuong et al[29], 2013	52	Yes	1.8-2.0	100%	39.5%	9.6%	26.9%	0	57.7%	11.5%	37.8%	28.8%
Koerber et al[30], 2014	68	Yes	1.8-2.2	\	47.1%		19.1%		63.2%		\	\	\
Current study	41	Yes	1.8-2.2	95%	26.8%	7.3%	9.8%	0	70.7%	4.9%	7.3%	4.9%	\

No. pts: Patients number; d/fx: Dose per fraction; CHT: Chemotherapy; SIB: Simultaneous integrated boost.